Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an update. Ascletis Pharma Inc. announced promising preclinical results for its ...

ASC47 is an adipose-targeted, once-monthly subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small ...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss ...

Ascletis Pharma’s new weight loss drug candidate, ASC47, combined with semaglutide, has shown promising results in preclinical trials, achieving more significant weight reduction and muscle ...

The ASC47-103 study, conducted in the U.S., is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability and preliminary efficacy of single-dose ...

The ASC47-103 study, conducted in the U.S., is a randomized, double-blind, placebo-controlled clinical study designed to evaluate the safety, tolerability and preliminary efficacy of single-dose ...

The ASC47-103 study consists of three cohorts: Cohort 1 participants receive a single dose of 10 mg ASC47, or volume-matched placebo via SQ injection, and four doses of semaglutide (0.5 mg, once ...

ASC47 has two additional Phase I studies in Australia: multiple ascending dose (MAD) study of ASC47 monotherapy in patients with obesity, and MAD study of ASC47 in combination with tirzepatide or ...